China NMPA accepts and grants priority review status to Hutchmed’s NDA for fanregratinib in second-line intrahepatic cholangiocarcinoma: Hong Kong, Shanghai Wednesday, December ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback